Exosome Effect on Prevention of Hairloss

Isfahan University of Medical Sciences20 enrolled

Overview

Many people suffer from alopecia, which is caused by hereditary factors, emotional stress, and psychiatric disorders. There are devastating physical and psychological consequences as a result. Exosomes are isolated from donated human amniotic mesenchymal stem cells and purified using specific processing. Exosomes are unique in that they are derived from stem cells and contain a wide range of growth factors. The latest generation of natural products for treating hair loss is exosomes.

Exosomes contain a variety of growth factors that are derived from stem cells. As they are so small, they can be hidden in the bloodstream and carry different types of proteins. The Wnt-β-catenin pathway is thought to play a major role in the pathogenesis of hair loss. The only FDA-approved medications for the treatment of hair loss are minoxidil (a vasodilator) and finasteride (a selective inhibitor of 5α reductase type II and III isoforms). However, these drugs have not been very perfect. Both have been associated with limited efficacy, duration of effect, and several significant side effects. Regenerative medicine using cell products is looking for a way to heal faster and less cost. Present research focus on Exosome efficacy on hairloss.

Study Type

INTERVENTIONAL

Allocation

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Hair Loss Alopecia

Interventions

ExosomeDEVICE

Each patients will receive 4 injection with an interval of 14 days during two months

Eligibility

Sex: ALLMin age: 25 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: subjects able to read the documents and have medical coverage Subjects have a "hair loss grade" as below criteria: 1. BASP grade: Basic type (M2 to M3, or C2 to C3, or U1 to U3) or Specific type (V1 to V3, or F1 to F3) 2. For female: Ludwig grade: Ⅰ to Ⅱ 3. For male: Norwood-Hamilton grade: III to IV 4. Hair density by phototrichogram: 60 to 190 hair/cm2 5. Telogen hair ≥ 5% Subject agreeing not to apply any topical treatment Subject agreeing to use a neutral shampoo Exclusion Criteria: 1. Sick subject in situation of emergency. 2. Subjects who have hereditary history of hairloss 3. Pregnant Females 4. Subject using topic cosmetic treatment or oral nutritional supplement likely to interfere on hair loss parameters during the last 3 months prior to the start of the study (screening) 5. Subjects who have a medical treatment for alopecia or having stopped it from than 3 months

Locations (1)

Leila Dehghani

Isfahan, Iran

RECRUITING

Outcomes

Primary Outcomes

Change in mean total hair density (hair/cm2)

Measurement of hair density by phototrichogram: change in mean total hair density (hair/cm\^2)

Time frame: 0 months

Change in mean total hair density (hair/cm2)

Measurement of hair density by phototrichogram: change in mean total hair density (hair/cm\^2)

Time frame: 3 months

Change in mean total hair density (hair/cm2)

Measurement of hair density by phototrichogram: change in mean total hair density (hair/cm\^2)

Time frame: 6 months

visual assessment before and after

Visual Assessment using the clinical picture by a general physician

Time frame: 6 months

Secondary Outcomes

Change in mean Telogen and Anagen hair density

Measurement of telogen and Anagen hair density before and after trial

Time frame: 0, months

Change in mean Telogen and Anagen hair density

Measurement of telogen and Anagen hair density before and after trial

Time frame: 3 months

Change in mean Telogen and Anagen hair density

Measurement of telogen and Anagen hair density before and after trial

Time frame: 6 months

Central Contacts

leila dehghani, Dr

CONTACT

+393517261300 l_dehghani2002@yahoo.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.